Population-based analysis characterizes lip lymphoma outcomes and treatment patterns, suggesting effective prognostic factors.
Background: Lip lymphoma is an exceptionally rare extranodal lymphoma with limited data to guide clinical management. We conducted the first large-scale population-based analysis to characterize its epidemiology, treatment patterns, and outcomes. Methods: We identified all lip lymphoma cases (2000-2022) from the SEER database (17 registries). Patients were categorized as localized primary lip lymphoma (LPLL, stage I) or lymphoma involving the lip area (LIL, stages II-IV). Results: Among 82 patients (median age 62 years, 54.9% female), age-adjusted incidence was 0.0459 per million per year. MALT lymphoma predominated (46.3%). With median follow-up of 74.5 months, 21 deaths (25.6%) occurred, only 5 (6.1%) lymphoma-related. Ten-year overall and cancer-specific survival rates were 72.7% and 92.6%, respectively. In multivariate analysis, age (HR 1.115/year, p<0.001) and non-low-grade histology (HR 3.251, p=0.043) independently predicted survival. All lymphoma-related deaths occurred in patients with aggressive or unknown histologies; none in confirmed low-grade B-cell lymphomas. No treatment strategy (surgery, radiotherapy, or systemic treatment) showed a significant superiority in terms of survival. Conclusion: Lip lymphoma demonstrates excellent prognosis, particularly for low-grade B-cell histologies. Age and histological grade represent principal prognostic factors guiding treatment strategies.
No takes yet. Share an insight, caveat, or question.
Loap et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: